<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">transmed</journal-id><journal-title-group><journal-title xml:lang="ru">Трансляционная медицина</journal-title><trans-title-group xml:lang="en"><trans-title>Translational Medicine</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2311-4495</issn><issn pub-type="epub">2410-5155</issn><publisher><publisher-name>Almazov National Medical Research Centre, Saint Petersburg, Russia</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.18705/2311-4495-2025-12-6-592-608</article-id><article-id custom-type="elpub" pub-id-type="custom">transmed-1052</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ЭКСПЕРИМЕНТАЛЬНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Experimental studies</subject></subj-group></article-categories><title-group><article-title>Применение специфичных для человека ИФА-наборов при анализе биоматериала лабораторных животных</article-title><trans-title-group xml:lang="en"><trans-title>Application of human-specific ELISA kits for the analysis of laboratory animal biomaterial</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6866-5741</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Фаустова</surname><given-names>Н. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Faustova</surname><given-names>N. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Наталья Михайловна Фаустова, кандидат химических наук, заместитель руководителя отдела</p><p>отдел технологии, кинетики и анализа лекарственных средств</p><p>188663; ул. Заводская, д. 3, к. 245, ком. 4.34; Ленинградская обл.; Кузьмоловский</p></bio><bio xml:lang="en"><p>Natalia M. Faustova, PhD, deputy of head of department</p><p>department of technology, kinetics and analysis of drugs</p><p>188663; 3 Zavodskaya str., bldg. 245, rm. 4.34; Leningrad Region; Kuzmolovsky</p></bio><email xlink:type="simple">faustova.nm@doclinika.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9690-1935</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Косман</surname><given-names>В. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Kosman</surname><given-names>V. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Вера Михайловна Косман, кандидат фармацевтических наук, заместитель руководителя отдела, ведущий научный сотрудник</p><p>отдел технологии, кинетики и анализа лекарственных средств</p><p>Ленинградская область; Кузьмоловский</p></bio><bio xml:lang="en"><p>Vera M. Kosman, PhD, deputy of head of department, leader researcher</p><p>department of technology, kinetics and analysis of drugs</p><p>Leningrad Region; Kuzmolovsky</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6292-8934</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Карлина</surname><given-names>М. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Karlina</surname><given-names>M. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Марина Валерьевна Карлина, кандидат биологическихнаук, руководитель отдела</p><p>отдел технологии, кинетики и анализа лекарственных средств</p><p>Ленинградская область; Кузьмоловский</p></bio><bio xml:lang="en"><p>Marina V. Karlina, PhD, head of department</p><p>department of technology, kinetics and analysis of drugs</p><p>Leningrad Region; Kuzmolovsky</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3176-6386</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Макарова</surname><given-names>М. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Makarova</surname><given-names>M. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Марина Николаевна Макарова, доктор медицинскихнаук, директор</p><p>Ленинградская область; Кузьмоловский</p></bio><bio xml:lang="en"><p>Marina N. Makarova, PhD, DSc, director</p><p>Leningrad Region; Kuzmolovsky</p></bio><email xlink:type="simple">makarova.mn@doclinika.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2447-7888</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Макаров</surname><given-names>В. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Makarov</surname><given-names>V. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Валерий Геннадиевич Макаров, доктор медицинских наук, профессор, научный руководитель</p><p>Ленинградская область; Кузьмоловский</p></bio><bio xml:lang="en"><p>Valeriy G. Makarov, PhD, DSc, Professor, Scientific Supervisor</p><p>Leningrad Region; Kuzmolovsky</p></bio><email xlink:type="simple">makarov.vg@doclinika.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Акционерное общество «Научно-производственное объединение «ДОМ ФАРМАЦИИ»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Research-and-manufacturing company «HOME OF PHARMACY»&#13;
Joint Stock Company</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>06</day><month>03</month><year>2026</year></pub-date><volume>12</volume><issue>6</issue><fpage>592</fpage><lpage>608</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Фаустова Н.М., Косман В.М., Карлина М.В., Макарова М.Н., Макаров В.Г., 2026</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="ru">Фаустова Н.М., Косман В.М., Карлина М.В., Макарова М.Н., Макаров В.Г.</copyright-holder><copyright-holder xml:lang="en">Faustova N.M., Kosman V.M., Karlina M.V., Makarova M.N., Makarov V.G.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://transmed.almazovcentre.ru/jour/article/view/1052">https://transmed.almazovcentre.ru/jour/article/view/1052</self-uri><abstract><sec><title>   Актуальность</title><p>   Актуальность. Иммуноферментный анализ (ИФА) широко применяют при изучении фармакологической безопасности, фармакокинетики, фармакодинамики как оригинальных, так и воспроизведенных (биоаналогичных) лекарственных веществ; он является методом выбора для оценки различных биомаркеров при проведении клинических и доклинических исследований. Особенностью, ограничивающей применение данного метода, является его видоспецифичность.</p></sec><sec><title>   Цель</title><p>   Цель. Статья посвящена обсуждению применения и адаптации специфичных для человека ИФА-наборов для анализа биоматериала лабораторных животных.</p></sec><sec><title>   Материалы и методы</title><p>   Материалы и методы. Рассмотрены материалы нескольких исследований, выполненных в организации, с использованием крыс как одной из наиболее распространенных тест-систем в доклинических исследованиях и включавших применение ИФА-наборов для определения в крови стероидных гормонов (тестостерон, эстрадиол), гормонов стресса (кортизол, кортикостерон) и кардиомаркеров (миоглобин, тропонин I).</p></sec><sec><title>   Результаты</title><p>   Результаты. Показаны примеры использования наборов реагентов без каких-либо изменений (кортизол), после различных вариантов оптимизации (кортикостерон, тестостерон, эстрадиол). На примере кардиомаркера миоглобина представлен алгоритм выбора типа биоматериала, позволяющий расширить исходную область применения набора реагентов и унифицировать отбор биоматериала в экспериментальном исследовании, а тропонин I оказался примером непригодности набора для анализа биоматериала крыс.</p></sec><sec><title>   Заключение</title><p>   Заключение. На основании экспериментального опыта сформулированы алгоритм и схема принятия решений по апробации и адаптации ИФА-наборов реагентов, специфичных для человека, при анализе биоматериала лабораторных животных.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>   Background</title><p>   Background. Enzyme-linked immunosorbent assay (ELISA) is widely used in the study of pharmacological safety, pharmacokinetics, pharmacodynamics of both original and reproduced (biosimilar) drugs; it is the method of choice for the evaluation of various biomarkers in clinical and preclinical studies. A feature limiting the use of this method is its species specificity.</p></sec><sec><title>   Objective</title><p>   Objective. The article discusses the use and adaptation of ELISA sets specific for humans for the analysis of biomaterial from laboratory animals.</p></sec><sec><title>   Design and methods</title><p>   Design and methods. The materials of several studies performed in the organization using rats as one of the most common test systems in preclinical studies, and including the use of ELISA kits for the determination of steroid hormones in the blood (testosterone, estradiol), stress hormones (cortisol, corticosterone) and cardiac biomarkers (myoglobin, troponin).</p></sec><sec><title>   Results</title><p>   Results. Examples of using reagent kits without any changes are shown (cortisol), after various optimization options (corticosterone, testosterone, estradiol). On the myoglobin cardiomarker example an algorithm for biomaterial type choosing is presented, which allows expanding the initial field of reagent kit use and unifying the biomaterial selection in an experimental study, and troponin I turned out to be an example of the unsuitability of the kit for analyzing rat biomaterial.</p></sec><sec><title>   Conclusion</title><p>   Conclusion. Based on experimental experience, an algorithm and decision-making scheme for approbation and adaptation of ELISA reagent kits specific for humans in the analysis of laboratory animal biomaterial are formulated.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>иммуноферментный анализ</kwd><kwd>адаптация наборов реагентов</kwd><kwd>видоспецифичность</kwd><kwd>плазма и/или сыворотка крови крыс</kwd><kwd>кортизол</kwd><kwd>кортикостерон</kwd><kwd>тестостерон</kwd><kwd>эстрадиол</kwd><kwd>тропонин I</kwd><kwd>миоглобин</kwd></kwd-group><kwd-group xml:lang="en"><kwd>enzyme-linked immunosorbent assay</kwd><kwd>reagent kit adaptation</kwd><kwd>species specificity</kwd><kwd>rat plasma and/&#13;
or serum</kwd><kwd>cortisol</kwd><kwd>corticosterone</kwd><kwd>testosterone</kwd><kwd>estradiol</kwd><kwd>troponin I</kwd><kwd>myoglobin</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Cox BM, Alsawah F, McNeill PC, et al. Neurochemical, hormonal, and behavioral effects of chronic unpredictable stress in the rat. Behavioural Brain Research. 2011;220(1):106–111. doi: 10.1016/j.bbr.2011.01.038</mixed-citation><mixed-citation xml:lang="en">Cox BM, Alsawah F, McNeill PC, et al. Neurochemical, hormonal, and behavioral effects of chronic unpredictable stress in the rat. Behavioural Brain Research. 2011;220(1):106–111. doi: 10.1016/j.bbr.2011.01.038</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Pereira VH, Marques F, Lages V, et al. Glucose intolerance after chronic stress is related with downregulated PPAR-γ in adipose tissue. Cardiovascular Diabetology. 2016;15(1):114. doi: 10.1186/s12933-016-0433-2</mixed-citation><mixed-citation xml:lang="en">Pereira VH, Marques F, Lages V, et al. Glucose intolerance after chronic stress is related with downregulated PPAR-γ in adipose tissue. Cardiovascular Diabetology. 2016;15(1):114. doi: 10.1186/s12933-016-0433-2</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">López AL, Villanueva ME, Padilla MB, et al. Chronic unpredictable mild stress progressively disturbs glucose metabolism and appetite hormones in rats. Acta endocrinologica. 2018;14(1):16–23. doi: 10.4183/aeb.2018.16</mixed-citation><mixed-citation xml:lang="en">López AL, Villanueva ME, Padilla MB, et al. Chronic unpredictable mild stress progressively disturbs glucose metabolism and appetite hormones in rats. Acta endocrinologica. 2018;14(1):16–23. doi: 10.4183/aeb.2018.16</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Oosterholt BG, Maes JHR, Van der Linden D, et al. Burnout and cortisol: Evidence for a lower cortisol awakening response in both clinical and non-clinical burnout. Journal of Psychosomatic Research. 2015;78(5):445–451. doi: 10.1016/j.jpsychores.2014.11.003</mixed-citation><mixed-citation xml:lang="en">Oosterholt BG, Maes JHR, Van der Linden D, et al. Burnout and cortisol: Evidence for a lower cortisol awakening response in both clinical and non-clinical burnout. Journal of Psychosomatic Research. 2015;78(5):445–451. doi: 10.1016/j.jpsychores.2014.11.003</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Меркулов В. М., Климова Н. В., Меркулова Т. И. Внутрисуточный ритм секреции глюкокортикоидов и динамика генного ответа. Вавиловский журнал генетики и селекции. 2015;19(2):214–221. doi: 10.18699/VJ15.027</mixed-citation><mixed-citation xml:lang="en">Merkulov VM, Klimova NV, Merkulova TI. The ultradian rhythm of glucocorticoid secretion and the time course of target gene regulation. Vavilov Journal of Genetics and selection. 2015;19(2):214–221. (In Russ.) doi: 10.18699/VJ15.027</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Morris CJ, Aeschbach D, Scheer FA. Circadian system, sleep and endocrinology. Mo.l Cell Endocrinol. 2012; 349(1):91–104. doi: 10.1016/j.mce.2011.09.003</mixed-citation><mixed-citation xml:lang="en">Morris CJ, Aeschbach D, Scheer FA. Circadian system, sleep and endocrinology. Mo.l Cell Endocrinol. 2012; 349(1):91–104. doi: 10.1016/j.mce.2011.09.003</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Lightman SL, Wiles CC, Atkinson HC et al. The significance of glucocorticoid pulsatility. European journal of pharmacology. 2008;583(2–3):255–262. doi: 10.1016/j.ejphar.2007.11.073</mixed-citation><mixed-citation xml:lang="en">Lightman SL, Wiles CC, Atkinson HC et al. The significance of glucocorticoid pulsatility. European journal of pharmacology. 2008;583(2–3):255–262. doi: 10.1016/j.ejphar.2007.11.073</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Nunes KP, de Oliveira AA, Szasz T et al. Blockade of toll-like receptor 4 attenuates erectile dysfunction in diabetic rats. J. Sex. Med. 2018;15(9):1235–1245. doi: 10.1016/j.jsxm.2018.07.005</mixed-citation><mixed-citation xml:lang="en">Nunes KP, de Oliveira AA, Szasz T et al. Blockade of toll-like receptor 4 attenuates erectile dysfunction in diabetic rats. J. Sex. Med. 2018;15(9):1235–1245. doi: 10.1016/j.jsxm.2018.07.005</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Al-Oanzi ZH. Erectile dysfunction attenuation by naringenin in streptozotocin-induced diabetic rats. J. Food Biochem. 2019;43(7):e12885. doi: 10.1111/jfbc.12885</mixed-citation><mixed-citation xml:lang="en">Al-Oanzi ZH. Erectile dysfunction attenuation by naringenin in streptozotocin-induced diabetic rats. J. Food Biochem. 2019;43(7):e12885. doi: 10.1111/jfbc.12885</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Yang BB, Hong ZW, Zhang Z, et al. Epalrestat, an aldose reductase inhibitor, restores erectile function in streptozocin-induced diabetic rats. Int. J. Impot. Res. 2019;31(2):97–104. doi: 10.1038/s41443-018-0075-x</mixed-citation><mixed-citation xml:lang="en">Yang BB, Hong ZW, Zhang Z, et al. Epalrestat, an aldose reductase inhibitor, restores erectile function in streptozocin-induced diabetic rats. Int. J. Impot. Res. 2019;31(2):97–104. doi: 10.1038/s41443-018-0075-x</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Yang R, Wang J, Chen Y, et al. Effect of caffeine on erectile function via up-regulating cavernous cyclic guanosine monophosphate in diabetic rats. J. Androl. 2008;29(5):586–591. doi: 10.2164/jandrol.107.004721</mixed-citation><mixed-citation xml:lang="en">Yang R, Wang J, Chen Y, et al. Effect of caffeine on erectile function via up-regulating cavernous cyclic guanosine monophosphate in diabetic rats. J. Androl. 2008;29(5):586–591. doi: 10.2164/jandrol.107.004721</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Luo L, Dai DZ, Cheng YS, et al. Sildenafil improves diabetic vascular activity through suppressing endothelin receptor A, iNOS and NADPH oxidase which is comparable with the endothelin receptor antagonist CPU0213 in STZ-injected rats. J. Pharm. Pharmacol. 2011;63(7):943–951. doi: 10.1111/j.2042-7158.2011.01268.x</mixed-citation><mixed-citation xml:lang="en">Luo L, Dai DZ, Cheng YS, et al. Sildenafil improves diabetic vascular activity through suppressing endothelin receptor A, iNOS and NADPH oxidase which is comparable with the endothelin receptor antagonist CPU0213 in STZ-injected rats. J. Pharm. Pharmacol. 2011;63(7):943–951. doi: 10.1111/j.2042-7158.2011.01268.x</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Зенкевич И. Г., Климова И. О. Применение метода стандартной добавки для количественного хроматографического анализа. Журнал аналитической химии. 2006;61(10): 1048–1054. doi: 10.1134/S1061934806100042</mixed-citation><mixed-citation xml:lang="en">Zenkevich IG, Klimova IO. Use of standard addition method in quantitative chromatographic analysis. J. of Analyt. Chem. 2006; 61(10):967–972. (In Russ.) doi: 10.1134/S1061934806100042</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Зенкевич И. Г., Морозова Т. Е. Особенности метода стандартной добавки для количественного определения аналитов в сложных смесях, обладающих сорбционными свойствами. Аналитика и контроль. 2010;14(3):164–171.</mixed-citation><mixed-citation xml:lang="en">Zenkevich IG, Morozova TE. Features of the method of standard addition for quantitation of analytes in complex mixtures with sorption properties. Analytics and Control. 2010;14(3):164–171. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Зенкевич И. Г., Бархатова Д. Д., Белышева М. Н. и др. Сравнительная характеристика различных вариантов количественного хроматографического анализа методом двойной стандартной добавки. Аналитика и контроль. 2021;25(2):146–154. doi: 10.15826/analitika.2021.25.2.010</mixed-citation><mixed-citation xml:lang="en">Zenkevich IG, Barkhatova DD, Belysheva MN, et al. Comparative characterization of different kinds of chromatographic quantification using the double standard addition method. Analytics and Control. 2021;25(2):146–154. (In Russ.) doi: 10.15826/analitika.2021.25.2.010</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Матичин А. А., Фаустова Н. М., Каргопольцева Д. Р. и др. Циркадианные колебания уровня тестостерона в плазме крови половозрелых самцов крыс. Лабораторные животные для научных исследований. 2020;2:36–42. doi: 10.29296/2618723X-2020-02-04</mixed-citation><mixed-citation xml:lang="en">Matichin AA, Faustova NM, Kargopolceva DR, et al. Circadian fluctuation in plasma testosterone levels in adult male rats. Laboratory Animals for Science. 2020;2:36–42. (In Russ.) doi: 10.29296/2618723X-2020-02-04</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Begemann K, Rawashdeh O, Olejniczak I, et al. Endocrine regulation of circadian rhythms. Biol Timing Sleep. 2025;2:10. doi: 10.1038/s44323-025-00024-6</mixed-citation><mixed-citation xml:lang="en">Begemann K, Rawashdeh O, Olejniczak I, et al. Endocrine regulation of circadian rhythms. Biol Timing Sleep. 2025;2:10. doi: 10.1038/s44323-025-00024-6</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Дымова О. В. Современные биомаркеры в кардиологии. Медицинский совет. 2018;(16):118–123. doi: 10.21518/2079-701X-2018-16-118–123</mixed-citation><mixed-citation xml:lang="en">Dymova OV. Modern biomarkers in cardiology. Medicinskij sovet. 2018;(16):118–123. (In Russ.) doi: 10.21518/2079-701X-2018-16-118-123</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Vittorini S, Clerico A. Cardiovascular biomarcers: increasing, impact of laboratory medicine in cardiology practice. Clinical Chemistry and Laboratory Medicine. 2008;46(6):748–763. doi: 10.1515/CCLM.2008.188</mixed-citation><mixed-citation xml:lang="en">Vittorini S, Clerico A. Cardiovascular biomarcers: increasing, impact of laboratory medicine in cardiology practice. Clinical Chemistry and Laboratory Medicine. 2008;46(6):748–763. doi: 10.1515/CCLM.2008.188</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Сапрыгин Д. Б. Кардиоспецифические тропонины: значение в диагностике, стратификации риска и прогнозе острого коронарного синдрома. 1. Диагностическое значение традиционных и современных маркеров миокардиального повреждения. Международный журнал интервенционной кардиоангиологии. 2003;2:65–70.</mixed-citation><mixed-citation xml:lang="en">Saprygin DB. Cardiospecific troponins: their significance in the diagnosis, risk stratification, and prognosis of acute coronary syndrome. 1. Diagnostic value of traditional and modern markers of myocardial damage. International Journal of Interventional Cardioangiology. 2003;2:65–70. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Vanek T, Kohli A. Biochemistry, myoglobin. StatPearls Treasure Island: StatPearls Publishing; 2025.</mixed-citation><mixed-citation xml:lang="en">Vanek T, Kohli A. Biochemistry, myoglobin. StatPearls Treasure Island: StatPearls Publishing; 2025.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Ordway GA, Garry DJ. Myoglobin: an essential hemoprotein in striated muscle. J. Exp. Biol. 2004;207(Pt20):3441–3446. doi: 10.1242/jeb.01172.</mixed-citation><mixed-citation xml:lang="en">Ordway GA, Garry DJ. Myoglobin: an essential hemoprotein in striated muscle. J. Exp. Biol. 2004;207(Pt20):3441–3446. doi: 10.1242/jeb.01172.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Катруха И. А. Тропониновый комплекс сердца человека. Структура и функции. Успехи биологической химии. 2013; 53:149–194.</mixed-citation><mixed-citation xml:lang="en">Katruha IA. Human cardiac troponin complex. Structure and functions. Uspekhi Biologicheskoi Khimii. 2013; 53:149–194. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Морроу Д., Кэннон К. П., Джесс Р. Л. и др. Руководство Национальной академии клинической биохимии по лабораторной медицинской практике: Клинические характеристики и использование биохимических маркеров при острых коронарных синдромах. Лабораторная диагностика. 2008.1(17):16–24.</mixed-citation><mixed-citation xml:lang="en">Morrou D, Kennon KP, Dzhess RL, et al. Guidelines of the National Academy of Clinical Biochemistry for laboratory medicine practice: Clinical characteristics and utilization of biochemical markers in acute coronary syndromes. Laboratory Diagnostics. 2008.1(17):16–24. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Kolmanová E, Bartošová L, Khazneh E, et al. Comparison of the specificity of cardiac troponin I and creatine kinase MB in isoproterenol-induced cardiotoxicity model in rats. Acta Veterinaria Brno. 2015;84(4):343–350. doi: 10.2754/avb201584040343</mixed-citation><mixed-citation xml:lang="en">Kolmanová E, Bartošová L, Khazneh E, et al. Comparison of the specificity of cardiac troponin I and creatine kinase MB in isoproterenol-induced cardiotoxicity model in rats. Acta Veterinaria Brno. 2015;84(4):343–350. doi: 10.2754/avb201584040343</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Clements P, Brady S, York M, et al. Time course characterization of serum cardiac troponins, heart fatty acid-binding protein, and morphologic findings with isoproterenol-induced myocardial injury in the rat. Toxicologic Pathology. 2010;38:703–714. doi: 10.1177/0192623310374969</mixed-citation><mixed-citation xml:lang="en">Clements P, Brady S, York M, et al. Time course characterization of serum cardiac troponins, heart fatty acid-binding protein, and morphologic findings with isoproterenol-induced myocardial injury in the rat. Toxicologic Pathology. 2010;38:703–714. doi: 10.1177/0192623310374969</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Березкин В. А., Бондарева Е. Д., Добрянская С. С. и др. Технологические процессы в доклинических исследованиях. Риск-ориентированный подход. Консультант GLP-Planet 2022. Мнение фармацевтической отрасли. Санкт-Петербург: Акционерное общество «Научно-производственное объединение «ДОМ ФАРМАЦИИ»; 2022. С. 152–173. doi: 10.57034/978-5-6048955-0-4-s7</mixed-citation><mixed-citation xml:lang="en">Berezkin VA, Bondareva ED, Dobryanskaya SS, et al. Technological processes in preclinical studies. A risk-based approach. Consultant GLP-Planet 2022. Pharmaceutical industry opinion. Saint Petersburg: Research-and-manufacturing company «HOME OF PHARMACY» Joint Stock Company; 2022. P. 152–173. (In Russ.) doi: 10.57034/978-5-6048955-0-4-s7</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Болсуновская Ю. Р., Енгалычева Г. Н., Ивкин Д. Ю. и др. Дизайн фармакологического эксперимента. Внедрение принципов ARRIVE в работу исследовательских центров. Консультант GLP-Planet 2022. Мнение фармацевтической отрасли. Санкт-Петербург: Акционерное общество «Научно-производственное объединение «ДОМ ФАРМАЦИИ»; 2022. С. 52–71. doi: 10.57034/978-5-6048955-0-4-s3</mixed-citation><mixed-citation xml:lang="en">Bolsunovskaya YuR, Engalycheva GN, Ivkin DYu, et al. Design of a pharmacological experiment. Implementation of the ARRIVE principles in research center operations. Consultant GLP-Planet 2022. Pharmaceutical industry opinion. Saint Petersburg: Research-and-manufacturing company «HOME OF PHARMACY» Joint Stock Company, 2022. P. 52–71. (In Russ.) doi: 10.57034/978-5-6048955-0-4-s3</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Piccoli SP. Points to consider document: scientific and regulatory considerations for the analytical validation of assays used in the qualification of biomarkers in biological matrices [Internet]. Biomarker Assay Collaborative Evidentiary Considerations Writing Group; 2019 [cited 2025 Apr 30]. Available from: https://media.c-path.org/wp-content/uploads/20240427170639/evidconsid-whitepaper-analyticalsectionv2019.pdf</mixed-citation><mixed-citation xml:lang="en">Piccoli SP. Points to consider document: scientific and regulatory considerations for the analytical validation of assays used in the qualification of biomarkers in biological matrices [Internet]. Biomarker Assay Collaborative Evidentiary Considerations Writing Group; 2019 [cited 2025 Apr 30]. Available from: https://media.c-path.org/wp-content/uploads/20240427170639/evidconsid-whitepaper-analyticalsectionv2019.pdf</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Косман В. М., Карлина М. В., Фаустова Н. М. и др. Вопросы валидации биоаналитических методик количественного определения биомаркеров : обзор нормативных документов. Регуляторные исследования и экспертиза лекарственных средств. 2025;15(5):550–564. doi: 10.30895/1991-2919-2025-766</mixed-citation><mixed-citation xml:lang="en">Kosman VM, Karlina MV, Faustova NM, et al. Validating bioanalytical methods for biomarker quantitation : a regulatory document review. Regulatory Research and Medicine Evaluation. 2025;15(5):550–564. doi: 10.30895/1991-2919-2025-766</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
